Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of 1 of the following: * Neuroblastoma * Rhabdomyosarcoma * Wilms tumor * Retinoblastoma * Adrenocortical carcinoma * Carcinoid tumor * Relapsed or refractory disease * Measurable or evaluable disease * No known curative therapy or therapy proven to prolong survival with an acceptable quality of life * No known pulmonary tumors or metastases \> 5 cm, as evaluated by chest CT scan * No clinically significant pulmonary and/or pericardial effusions (≥ grade 3), as evaluated by ECHO * No primary CNS tumors or known metastatic CNS disease involvement PATIENT CHARACTERISTICS: * Karnofsky performance status (PS) 50-100% (for patients \> 16 years of age) * Lansky PS 50-100% (for patients ≤ 16 years of age) * Peripheral ANC ≥ 1,000/mm\^3 * Platelet count ≥ 100,000/mm\^3 (transfusion independent, defined as no platelet transfusions within a 7-day period before study enrollment) * Hemoglobin ≥ 8.0 g/dL (RBC transfusions allowed) * Creatine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine based on age/gender as follows: * ≤ 0.8 mg/dL (for patients 3 to 5 years of age) * ≤ 1.0 mg/dL (for patients 6 to 9 years of age) * ≤ 1.2 mg/dL (for patients 10 to 12 years of age) * ≤ 1.4 mg/dL (for female patients ≥ 13 years of age) * ≤ 1.5 mg/dL (for male patients 13 to 15 years of age) * ≤ 1.7 mg/dL (for male patients ≥ 16 years of age) * Bilirubin (sum of conjugated and unconjugated) ≤ 1.5 times …